Enphase Energy Inc vs Cassava Sciences Inc — how do they compare? Enphase Energy Inc trades at $41.07 (market cap $5.81B), while Cassava Sciences Inc trades at $1.1 (market cap $53.14M). The key difference: Enphase Energy Inc is far larger — about 109.3× Cassava Sciences Inc's market cap, and Enphase Energy Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ENPH | FLNA | |
|---|---|---|
Market Cap | $5.81B | $53.14M |
Sector | Technology | Health |
52-Week High | $72.33 | $4.64 |
52-Week Low | $26.12 | $1.09 |
Enterprise Value | $5.46B | -$33.43M |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $41.59, down 7.55% in the past 24 hours, reflecting recent bearish pressure. The stock shows a mixed technical picture with support near $39 and resistance at $44, while fundamentals indicate solid profitability with a 44.23% gross margin and consistent earnings beats in recent quarters. Recent news highlights product expansions in Europe and Australia, alongside positive analyst coverage citing long-term tailwinds despite short-term challenges.
Outlook remains cautiously optimistic with a consensus price target of $42.79, slightly above current levels. Key opportunities include global product rollouts and high margins, but risks involve revenue volatility, competitive pressures, and ongoing legal scrutiny. Investors should weigh strong fundamentals against near-term stock weakness and market sentiment shifts.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trailing returns across standard periods
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →